Effect of Psychobiotics With Standard Antiddepressants in Treatment of Major Depressive Disorder
In plain words A study of lactobacillus helveticus in people 18 to 60, run by Dr Sadia yasir. It plans to enroll about 86 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Major Depression.
- Patients diagnosed with major depressive disorder (According to Diagnostic \& Statistical Manual-5 criteria (as per operational definition)
- Age 18 to 60 years
- Both genders
- Patients who are able to speak and understand Urdu/ English language.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Lactobacillus Helveticus and bifidobacterium Longum; Placebo Capsule(s)
Registered summary
The goal of this clinical trial is to learn whether adding psychobiotics (a combination of Lactobacillus helveticus and Bifidobacterium longum) to standard antidepressant treatment works better than antidepressants alone for adults with major depressive disorder. The study will also learn about the safety of taking these psychobiotics with antidepressants. The main questions it aims to answer are: 1. Does adding psychobiotics lower depression symptoms more than a placebo (a look-alike capsule with no active ingredients)? 2. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).